Dosing & Uses
Dosage Forms & Strengths
injectable solution
- 10mg/mL
Severe/Malignant Hypertension, Hypertensive Emergencies
Initiate dosing at 0.01 to 0.3 mcg/kg/min by continuous IV infusion
Titrate by 0.05-0.1 mcg/kg/min q15min or longer until target blood pressure reached; up to 1.6 mcg/kg/min used in clinical trials; may continue maintenance infusion for up to 48 hr
In hospital use only
Monitor
Continuously monitor BP (usually by means of an intra-arterial line) & heart rate
Other Indications & Uses
Short-term (No more than 48 hr adult, 4 hr Peds), in-hospital treatment of
- Severe or malignant hypertension
- Hypertensive emergencies
Dosage Forms & Strengths
injectable solution
- 10mg/mL
Severe/Malignant HTN, Hypertensive Emergencies
Initial 0.2 mcg/kg/min continuous IV infusion pump for <4 hr
Titrate q20-30min up to 0.3-0.5 mcg/kg/min; not to exceed 0.8 mcg/kg/min
In hospital use only
Monitor
Continuously monitor BP (usually by means of an intra-arterial line) & heart rate
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (4)
- amisulpride
amisulpride, fenoldopam. Either decreases effects of the other by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid use of amisulpride, a dopamine receptor antagonist, with dopamine agonists.
- lofexidine
lofexidine, fenoldopam. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension.
- metoclopramide intranasal
metoclopramide intranasal, fenoldopam. dopaminergic effects. Avoid or Use Alternate Drug. Opposing effects of metoclopramide and the interacting drug on dopamine. Potential exacerbation of symptoms (eg, parkinsonian symptoms) or decreased therapeutic effects of metoclopramide.
- ozanimod
ozanimod increases toxicity of fenoldopam by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use.
Monitor Closely (14)
- aldesleukin
aldesleukin increases effects of fenoldopam by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension.
- amifostine
amifostine, fenoldopam. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine.
- bretylium
fenoldopam, bretylium. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Each drug may cause hypotension.
- carbidopa
carbidopa increases effects of fenoldopam by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required.
- dichlorphenamide
dichlorphenamide and fenoldopam both decrease serum potassium. Use Caution/Monitor.
- epoprostenol
epoprostenol, fenoldopam. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.
- hydralazine
fenoldopam, hydralazine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.
- iloprost
fenoldopam, iloprost. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.
- levodopa
levodopa increases effects of fenoldopam by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent.
- maraviroc
maraviroc, fenoldopam. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of orthostatic hypotension.
- minoxidil
fenoldopam, minoxidil. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.
- solriamfetol
fenoldopam and solriamfetol both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor.
- treprostinil
fenoldopam, treprostinil. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor.
- xipamide
xipamide increases effects of fenoldopam by pharmacodynamic synergism. Use Caution/Monitor.
Minor (25)
- acebutolol
fenoldopam increases effects of acebutolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- agrimony
agrimony increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown.
- atenolol
fenoldopam increases effects of atenolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- betaxolol
fenoldopam increases effects of betaxolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- bisoprolol
fenoldopam increases effects of bisoprolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- brimonidine
brimonidine increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown.
- carvedilol
fenoldopam increases effects of carvedilol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- celiprolol
fenoldopam increases effects of celiprolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- cornsilk
cornsilk increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown.
- esmolol
fenoldopam increases effects of esmolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- forskolin
forskolin increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown.
- labetalol
fenoldopam increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- maitake
maitake increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown. Maitake mushroom has anti-tumor effects (animal/in vitro research).
- metoprolol
fenoldopam increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- nadolol
fenoldopam increases effects of nadolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- nebivolol
fenoldopam increases effects of nebivolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- penbutolol
fenoldopam increases effects of penbutolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- pindolol
fenoldopam increases effects of pindolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- propranolol
fenoldopam increases effects of propranolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- reishi
reishi increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown.
- shepherd's purse
shepherd's purse, fenoldopam. Other (see comment). Minor/Significance Unknown. Comment: Theoretically, shepherd's purse may interfere with BP control.
- sotalol
fenoldopam increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- timolol
fenoldopam increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.
- tizanidine
tizanidine increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.
- treprostinil
treprostinil increases effects of fenoldopam by pharmacodynamic synergism. Minor/Significance Unknown.
Adverse Effects
Frequency Not Defined
Angina
Cardiac dysrhythmia
Dizziness
Flushing
Heart failure
Hypotension
Myocardial infarction
Tachycardia
Headache
Nausea
Vomiting
Serum creatinine raised
Postmarketing Reports
Cardiac disorders: Cardiogenic shock
Gastrointestinal disorders: Abdominal distension
Warnings
Contraindications
None
Cautions
Causes a dose-related tachycardia, particularly with infusion rates above 0.1 mcg/kg/min; tachycardia in adults may diminish with continued therapy at doses of fenoldopam of <0.1 mcg/kg/min
Hypokalemia has been observed after < 6 hours of infusion; hypokalemia reflects a pressure natriuresis with enhanced potassium-sodium exchange or a direct drug effect; monitor serum potassium levels
Increased intraocular pressure in patients with glaucoma or intraocular hypertension reported
Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms in susceptible patients; overall prevalence of sulfite sensitivity in general population is unknown and probably low; sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people
Pregnancy & Lactation
Pregnancy
There are insufficient data regarding use in pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes
Severe hypertension can result in maternal stroke, pulmonary edema, myocardial ischemia or death of the mother or fetus
Animal data
- In animal studies, there was no evidence of teratogenicity or fetotoxicity when fenoldopam was orally administered to rats and rabbits during organogenesis; there are adverse effects on maternal and fetal outcomes associated with severe hypertension
Lactation
There are no data on presence of drug in human milk, effects on breastfed child, or on milk production; drug is present in rat milk; when a drug is present in animal milk, it is likely that the drug will be present in human milk
Because of potential for severe adverse reactions in breastfed infant, advise women not to breastfeed during treatment
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
D1-dopamine receptor agonist: rapid-acting vasodilator; decreases peripheral resistance and increases renal blood flow; has minimal adrenergic effects
Also diuretic, natriuretic
Pharmacokinetics
Half-Life: 5 min
Duration: 1-4 hr post infusion
Onset: initial effect: 10 min, max effect: 30-120 min
Vd: 0.6 L/kg
Metabolism: in the liver to a variety of sulfate, glucuronide, & methoxy metabolites
Metabolite: fenoldopam-8-sulfate, fenoldopam-7-sulfate, fenoldopam glucuronide conjugates, and other minor metabolites
Excretion: Urine (90%), feces (10%)
Administration
IV Incompatibilities
Y-site: aminophylline, amphotericin B, ampicillin, bumetanide, cefoxitin, dexamethasone sodium PO4, diazepam, fosphenytoin, furosemide, ketorolac, methohexital, methylprednisolone Na-succinate, pentobarbital, phenytoin, prochlorperazine, Na-bicarb, thiopental
IV Compatibilities
Solution: D5W, NS
Y-site (partial list): alfentanil, atropine, cefazolin, cefepime, ciprofloxacin, cisatracurium, clindamycin, dalfopristin-quinupristin, digoxin, diltiazem, dobutamine, dopamine, epinephrine, erythromycin, esmolol, heparin, hydromorphone, hydroxyzine, linezolid, lorazepam, MgSO4, morphine SO4, mannitol, midazolam, nitroglycerin, KCl, propofol, propranolol, TMP-SMX, vancomycin, verapamil
IV Preparation
Adult Infusion: dilute in NS or D5W to a final concentration of 40 mcg/mL; for each 1 mL (=10 mg) of drug use 250 mL diluent
Pediatric Infusion: dilute in NS or D5W to a final concentration of 60 mcg/mL; for each 1.5 mL (=15 mg) of drug use 250 mL diluent
IV Administration
Use diluted solution within 24 hr
Use continuous infusion pump
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Corlopam intravenous - | 10 mg/mL vial |  | |
| Corlopam intravenous - | 10 mg/mL vial |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
fenoldopam intravenous
NO MONOGRAPH AVAILABLE AT THIS TIME
USES: Consult your pharmacist.
HOW TO USE: Consult your pharmacist.
SIDE EFFECTS: Consult your pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Consult your pharmacist.
DRUG INTERACTIONS: Consult your pharmacist.Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: No monograph available at this time.
MISSED DOSE: Consult your pharmacist.
STORAGE: Consult your pharmacist.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
Information last revised July 2016. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
